- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 (10) | -0.24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2023 (9) | -3.53 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2022 (8) | -4.56 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2021 (7) | 6.65 | 0 | 0.00 | 0 | 4.83 | 0 | 0.00 | 0 | 72.63 | 0 | 72.63 | 0 |
| 2020 (6) | -3.61 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2019 (5) | -3.97 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2018 (4) | -3.17 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2017 (3) | -2.64 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 25Q2 (20) | -0.30 | -400.0 | -850.0 | -0.19 | -90.0 | -1800.0 | -0.37 | -516.67 | -105.56 |
| 25Q1 (19) | -0.06 | 14.29 | 72.73 | -0.10 | 28.57 | 68.75 | -0.06 | 75.0 | 72.73 |
| 24Q4 (18) | -0.07 | 0 | 96.05 | -0.14 | -566.67 | 91.46 | -0.24 | -33.33 | 93.2 |
| 24Q3 (17) | 0.00 | -100.0 | 100.0 | 0.03 | 400.0 | 111.54 | -0.18 | 0.0 | 89.77 |
| 24Q2 (16) | 0.04 | 118.18 | 104.17 | -0.01 | 96.88 | 99.07 | -0.18 | 18.18 | 88.75 |
| 24Q1 (15) | -0.22 | 87.57 | 66.15 | -0.32 | 80.49 | 52.24 | -0.22 | 93.77 | 66.15 |
| 23Q4 (14) | -1.77 | -1006.25 | 20.27 | -1.64 | -530.77 | 21.53 | -3.53 | -100.57 | 22.59 |
| 23Q3 (13) | -0.16 | 83.33 | 83.16 | -0.26 | 75.7 | 76.58 | -1.76 | -10.0 | 25.11 |
| 23Q2 (12) | -0.96 | -47.69 | 33.33 | -1.07 | -59.7 | -12.63 | -1.60 | -146.15 | 23.81 |
| 23Q1 (11) | -0.65 | 70.72 | 1.52 | -0.67 | 67.94 | -48.89 | -0.65 | 85.75 | 1.52 |
| 22Q4 (10) | -2.22 | -133.68 | -144.14 | -2.09 | -88.29 | -166.35 | -4.56 | -94.04 | -168.57 |
| 22Q3 (9) | -0.95 | 34.03 | -129.69 | -1.11 | -16.84 | -156.63 | -2.35 | -11.9 | -244.17 |
| 22Q2 (8) | -1.44 | -118.18 | -71.43 | -0.95 | -111.11 | 30.66 | -2.10 | -218.18 | -32.08 |
| 22Q1 (7) | -0.66 | -113.12 | 10.81 | -0.45 | -114.29 | 47.06 | -0.66 | -109.92 | 10.81 |
| 21Q4 (6) | 5.03 | 57.19 | 603.0 | 3.15 | 60.71 | 503.85 | 6.65 | 307.98 | 284.21 |
| 21Q3 (5) | 3.20 | 480.95 | 426.53 | 1.96 | 243.07 | 421.31 | 1.63 | 202.52 | 161.28 |
| 21Q2 (4) | -0.84 | -13.51 | 0.0 | -1.37 | -61.18 | 0.0 | -1.59 | -114.86 | 0.0 |
| 21Q1 (3) | -0.74 | 26.0 | 0.0 | -0.85 | -8.97 | 0.0 | -0.74 | 79.5 | 0.0 |
| 20Q4 (2) | -1.00 | -2.04 | 0.0 | -0.78 | -27.87 | 0.0 | -3.61 | -35.71 | 0.0 |
| 20Q3 (1) | -0.98 | 0.0 | 0.0 | -0.61 | 0.0 | 0.0 | -2.66 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025/8 | 0.46 | -18.21 | -17.6 | 3.62 | 2.13 | 1.58 | N/A | - | ||
| 2025/7 | 0.56 | -0.96 | -14.04 | 3.16 | 5.8 | 1.59 | N/A | - | ||
| 2025/6 | 0.56 | 21.75 | 12.44 | 2.6 | 11.32 | 1.45 | 3.51 | - | ||
| 2025/5 | 0.46 | 10.35 | -44.79 | 2.04 | 11.01 | 1.34 | 3.79 | - | ||
| 2025/4 | 0.42 | -7.92 | 2.51 | 1.57 | 58.09 | 1.21 | 4.18 | 本年累計營收較去年成長，主係市場需求增加 | ||
| 2025/3 | 0.46 | 34.95 | 73.14 | 1.15 | 96.97 | 1.15 | 4.13 | - | ||
| 2025/2 | 0.34 | -5.95 | 140.68 | 0.7 | 116.46 | 1.07 | 4.47 | - | ||
| 2025/1 | 0.36 | -2.79 | 97.75 | 0.36 | 97.75 | 1.08 | 4.4 | - | ||
| 2024/12 | 0.37 | 4.29 | 57.32 | 6.06 | 55.44 | 1.29 | 3.51 | - | ||
| 2024/11 | 0.35 | -37.02 | -43.84 | 5.69 | 55.32 | 2.14 | 2.11 | - | ||
| 2024/10 | 0.56 | -53.99 | -33.44 | 5.33 | 76.0 | 2.34 | 1.93 | - | ||
| 2024/9 | 1.22 | 120.58 | 4.95 | 4.77 | 118.44 | 2.43 | 1.78 | - | ||
| 2024/8 | 0.56 | -14.67 | -45.37 | 3.54 | 248.71 | 1.71 | 2.54 | - | ||
| 2024/7 | 0.65 | 29.54 | 0.0 | 2.99 | 0.0 | 1.99 | 2.17 | - | ||
| 2024/6 | 0.5 | -40.21 | 0.0 | 2.34 | 0.0 | 1.75 | 2.7 | - | ||
| 2024/5 | 0.84 | 104.9 | 0.0 | 1.84 | 0.0 | 1.51 | 3.12 | . | ||
| 2024/4 | 0.41 | 55.52 | 0.0 | 1.0 | 0.0 | 0.81 | 5.81 | . | ||
| 2024/3 | 0.26 | 87.59 | 0.0 | 0.59 | 0.0 | 0.59 | 6.96 | . | ||
| 2024/2 | 0.14 | -22.73 | 0.0 | 0.32 | 0.0 | 0.56 | 7.32 | . | ||
| 2024/1 | 0.18 | -22.66 | 0.0 | 0.18 | 0.0 | 1.05 | 3.89 | . | ||
| 2023/12 | 0.24 | -62.77 | 305.88 | 3.9 | 6.73 | 1.71 | 2.24 | . | ||
| 2023/11 | 0.63 | -25.35 | 601.27 | 3.66 | 1.9 | 2.64 | 1.45 | . | ||
| 2023/10 | 0.85 | -27.44 | 848.06 | 3.03 | -13.5 | 3.03 | 1.27 | . | ||
| 2023/9 | 1.17 | 14.79 | 10196.5 | 2.18 | -36.04 | 2.18 | 3.85 | . | ||
| 2023/8 | 1.02 | 0.0 | 24154.4 | 1.02 | -70.12 | 1.02 | 8.28 | . | ||
| 2023/7 | 0.0 | 0.0 | -100.0 | 0.0 | -100.0 | 0.0 | 0 | . | ||
| 2023/6 | 0.0 | 0.0 | -100.0 | 0.0 | -100.0 | 0.0 | 0 | . | ||
| 2023/5 | 0.0 | 0.0 | -100.0 | 0.0 | -100.0 | 0.0 | 0 | . | ||
| 2023/4 | 0.0 | 0.0 | -100.0 | 0.0 | -100.0 | 0.0 | 0 | . | ||
| 2023/3 | 0.0 | 0.0 | -100.0 | 0.0 | -100.0 | 0.0 | 0 | . | ||
| 2023/2 | 0.0 | 0.0 | -100.0 | 0.0 | -100.0 | 0.06 | 93.2 | . | ||
| 2023/1 | 0.0 | -100.0 | -100.0 | 0.0 | -100.0 | 0.15 | 36.48 | . | ||
| 2022/12 | 0.06 | -35.68 | -97.97 | 3.65 | -88.87 | 0.24 | 22.97 | . | ||
| 2022/11 | 0.09 | 0.9 | -99.22 | 3.59 | -88.0 | 0.19 | 28.58 | . | ||
| 2022/10 | 0.09 | 687.99 | -98.47 | 3.5 | -80.93 | 0.1 | 52.0 | . | ||
| 2022/9 | 0.01 | 170.4 | -99.78 | 3.41 | -72.71 | 0.02 | 357.69 | . | ||
| 2022/8 | 0.0 | -22.69 | -99.94 | 3.4 | -53.53 | 0.03 | 267.79 | . | ||
| 2022/7 | 0.01 | -70.47 | 18.59 | 3.4 | 7395.23 | 0.05 | 159.46 | . | ||
| 2022/6 | 0.02 | -20.82 | 96.78 | 3.39 | 8222.3 | 0.13 | 59.6 | . | ||
| 2022/5 | 0.02 | -72.48 | 0.0 | 3.37 | 10634.4 | 0.99 | 7.61 | . | ||
| 2022/4 | 0.08 | -90.4 | 0.0 | 3.35 | 10560.6 | 0.99 | 7.55 | . | ||
| 2022/3 | 0.88 | 2795.38 | 7583.02 | 3.27 | 10292.4 | 3.27 | 1.82 | . | ||
| 2022/2 | 0.03 | -98.71 | 0.0 | 2.39 | 11840.8 | 5.25 | 1.13 | . | ||
| 2022/1 | 2.36 | -17.62 | 11689.2 | 2.36 | 11689.2 | 16.79 | 0.35 | . | ||
| 2021/12 | 2.86 | -75.26 | 8437.1 | 32.81 | 28415.5 | 20.3 | 0.28 | 自110年8月新冠肺炎疫苗開始銷售 | ||
| 2021/11 | 11.57 | 97.27 | 51652.5 | 29.95 | 36631.8 | 22.63 | 0.25 | 自110年8月新冠肺炎疫苗開始銷售 | ||
| 2021/10 | 5.87 | 13.04 | 43773.2 | 18.38 | 30955.6 | 18.33 | 0.31 | 自110年8月新冠肺炎疫苗開始銷售 | ||
| 2021/9 | 5.19 | -28.67 | 29619.2 | 12.51 | 27213.8 | 12.47 | 0.65 | 自110年8月新冠肺炎疫苗開始銷售 | ||
| 2021/8 | 7.28 | 159100.0 | 127989.0 | 7.32 | 25731.9 | 7.29 | 1.11 | 新冠肺炎疫苗開始銷售 | ||
| 2021/7 | 0.0 | -51.01 | -28.03 | 0.05 | 100.04 | 0.01 | 579.86 | . | ||
| 2021/6 | 0.01 | 0.0 | -3.61 | 0.04 | 149.9 | 0.01 | 804.93 | . | ||
| 2021/5 | 0.0 | 0.0 | -100.0 | 0.03 | 374.05 | 0.01 | 657.04 | . | ||
| 2021/4 | 0.0 | -100.0 | 0.0 | 0.03 | 554.79 | 0.01 | 657.04 | . | ||
| 2021/3 | 0.01 | 0.0 | 0.0 | 0.03 | 554.79 | 0.03 | 29.27 | . | ||
| 2021/2 | 0.0 | -100.0 | 0.0 | 0.02 | 316.66 | 0.05 | 17.19 | . | ||
| 2021/1 | 0.02 | -40.35 | 316.66 | 0.02 | 316.66 | 0.08 | 12.12 | . | ||
| 2020/12 | 0.03 | 49.95 | 0.0 | 0.12 | 927.32 | 0.07 | 11.12 | . | ||
| 2020/11 | 0.02 | 67.24 | 0.0 | 0.08 | 627.94 | 0.05 | 14.48 | . | ||
| 2020/10 | 0.01 | -23.42 | 178.54 | 0.06 | 428.3 | 0.0 | N/A | . | ||
| 2020/9 | 0.02 | 207.39 | 0.0 | 0.05 | 615.62 | 0.0 | N/A | . |
免責聲明
本網站所有資料僅供參考，如使用者依本資料交易發生交易損失需自行負責，本網站對資料內容錯誤﹑更新延誤不負任何責任。